Login / Signup

The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer.

Jing ZhaoYang WuYuan YueMin-Jiang ChenYan XuXiangning LiuXiaoyan LiuXiaoxing GaoHanping WangXiao-Yan SiWei ZhongXiao-Tong ZhangLi ZhangMengzhao Wang
Published in: Thoracic cancer (2023)
Collectively, our study developed and validated two TAAb panels as valuable prognostic biomarkers for immunotherapy.
Keyphrases
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • systemic lupus erythematosus
  • tyrosine kinase